Insmed Targets Raised to $211 and $166 as Brinsupri 2026 Sales Aim $1B
BofA raised its Insmed price target to $211 and kept a Buy rating, citing fiscal 2026 Brinsupri sales guidance of at least $1B supporting commercial scale-up confidence. Morgan Stanley raised its target to $166, citing potential U.S. market expansion and noting 2025 revenues reached $606.4M with Brinsupri at $172.7M.
1. Analyst Price Target Increases
Bank of America raised its Insmed price target to $211 from $209 and maintained a Buy rating, while Morgan Stanley lifted its target to $166 from $162 and reiterated an Equal Weight rating.
2. Brinsupri 2026 Sales Outlook Strengthened
Insmed updated its fiscal 2026 Brinsupri guidance to sales of at least $1 billion, underpinning confidence in the drug’s commercial scale-up and revenue durability.
3. 2025 Revenue Performance Exceeds Guidance
Insmed reported full-year 2025 revenues of $606.4 million, driven by Brinsupri sales of $172.7 million and ARIKAYCE revenues of $433.8 million, with ARIKAYCE Q4 sales of $119.2 million representing 19% year-over-year growth.
4. Addressable Market Expansion Offers Upside
Management commentary highlighted potential expansion of the U.S. addressable market for Brinsupri beyond initial estimates, suggesting incremental revenue upside and signaling a pivotal inflection point for operating leverage in 2026.